Full details of the evidence and the committee's discussion are in evidence review E and F: risk stratification tools for predicting bleeding in people with atrial fibrillation. 1.3 Assessment of cardiac function 1.3.1 Perform transthoracic echocardiography (TTE) in people with atrial fibrillation: for whom a baseline echocardiogram is important for long-term management for whom a rhythm-control strategy that includes cardioversion (electrical or pharmacological) is being considered in whom there is a high risk or a suspicion of underlying structural or functional heart disease (such as heart failure or heart murmur) that influences their subsequent management (for example, choice of antiarrhythmic drug) in whom refinement of clinical risk stratification for antithrombotic therapy is needed (see section 1.2 on assessment of stroke and bleeding risks and section 1.6 on stroke prevention). [2006, amended 2014] 1.3.2 Do not routinely perform TTE solely for the purpose of further stroke risk stratification in people with atrial fibrillation for whom the need to start anticoagulation therapy has already been agreed on appropriate clinical criteria (see section 1.2 on assessment of stroke and bleeding risks and section 1.6 on stroke prevention). [2006, amended 2014] 1.3.3 Perform transoesophageal echocardiography (TOE) in people with atrial fibrillation: when TTE demonstrates an abnormality (such as valvular heart disease) that warrants further specific assessment in whom TTE is technically difficult and/or of questionable quality and when there is a need to exclude cardiac abnormalities for whom TOE-guided cardioversion is being considered. [2006] 1.4 Personalised package of care and information 1.4.1 Offer people with atrial fibrillation a personalised package of care. 